SAN DIEGO, May 4, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), announced today that the results of two studies of torezolid phosphate (TR-701) will be presented at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Milan, Italy on May 7th – 10th. Torezolid phosphate is a fast-acting, bactericidal 2nd generation IV and oral oxazolidinone.
